Gracell Biotechnologies EBIT

Gracell Biotechnologies posts a EBIT of $-580M as of September 2023. That compares with $-620M in the prior-year period — up 6.0% year over year. That is below the Healthcare sector average of $23B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Gracell Biotechnologies's EBIT was $-620M. The latest reading is $-580M — a 6.0% year-over-year increase (period ending September 2023). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a EBIT near $23B is typical. Gracell Biotechnologies's $-580M is lower that level. That is roughly 102.5% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

EBIT is one piece of Gracell Biotechnologies's financial statement story. At $-580M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for GRCL's EBIT usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $23B), and (3) consistency with growth and profitability. This page covers the first two; Gracell Biotechnologies's other metric pages and overview cover the third.